COST-EFFECTIVENESS OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL, CAR-T) FOR THE TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN GREECE

被引：0
|
作者：
Loupas, M. A. [1 ]
Theodoratou, D. [2 ]
Kourlaba, G. [1 ]
机构：
[1] Econcare LP, Athens A1, Greece
[2] Gilead Sci Hellas, Palaio Faliro, Greece
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE298
引用
收藏
页码：S112 / S112
页数：1
相关论文
共 50 条
  • [41] Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3
    Oluwole, Olalekan O.
    Ghobadi, Armin
    Cassaday, Ryan Daniel
    Park, Jae H.
    Houot, Roch
    Logan, Aaron
    Boissel, Nicolas
    Leguay, Thibaut
    Bishop, Michael Russell
    Topp, Max S.
    O'Dwyer, Kristen M.
    Baer, Maria R.
    Schiller, Gary J.
    Abedi, Mehrdad
    Minnema, Monique C.
    Stiff, Patrick J.
    Zhou, Lang
    Siddiqi, Rubina
    Khalid, Rita Damico
    Shah, Bijal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] COST-EFFECTIVENESS OF BREXUCABTAGENE AUTOLEUCEL FOR THE TREATMENT OF RELAPSED/ REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN PATIENTS AGED 26 YEARS OR OLDER IN THE UNITED KINGDOM
    Spousta, T.
    Feng, C.
    van Hees, F.
    Wade, S.
    Doble, B.
    VALUE IN HEALTH, 2023, 26 (12) : S156 - S156
  • [43] Cost-Effectiveness of KTE-X19 Car T Therapy Following Bruton Tyrosine Kinase Inhibitor Treatment for Relapsed/Refractory Mantle Cell Lymphoma in England
    Maglinte, Gregory A.
    Simons, Claire L.
    Wang, Michael
    Wade, Sally W.
    Brown, Martin
    Petersohn, Svenja
    Bennison, Craig
    Dreyling, Martin
    BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 195 - 196
  • [44] Cladribine and Cyclophosphamide Lymphodepletion Prior to Brexucabtagene Autoleucel in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma
    Ionescu, Filip
    Faramand, Rawan
    Bailey, Hanna
    Bachmeier, Christina A.
    DiMaggio, Elizabeth
    Mohammed, Turab
    Isenalumhe, Leidy Lismeris
    Locke, Frederick L.
    Jain, Michael D.
    Shah, Bijal D.
    BLOOD, 2023, 142
  • [45] Brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma (R/R MCL) in ZUMA-2: Durable responder analysis
    Munoz, Javier
    Reagan, Patrick M.
    Goy, Andre
    Miklos, David B.
    Zheng, Dan
    Fang, Xiang
    Shen, Rhine R.
    Siddiqi, Rubina
    Kloos, Ioana
    Kersten, Marie Jose
    Wang, Michael
    ANNALS OF ONCOLOGY, 2023, 34 : S1380 - S1380
  • [46] Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma: Is It Time to Consider CAR-T for All
    Zelenetz, Andrew D.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (12): : 1764 - 1766
  • [47] Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma
    Anderson, Mary Kate
    Torosyan, Annie
    Halford, Zachery
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (05) : 609 - 619
  • [48] Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
    Hess, Georg
    Dreyling, Martin
    Oberic, Lucie
    Gine, Eva
    Zinzani, Pier Luigi
    Linton, Kim
    Vilmar, Adam
    Jerkeman, Mats
    Chen, Jenny M. H.
    Ohler, Anke
    Stilgenbauer, Stephan
    Thieblemont, Catherine
    Lambert, Jonathan
    Zilioli, Vittorio Ruggero
    Sancho, Juan-Manuel
    Jimenez-Ubieto, Ana
    Fischer, Luca
    Eyre, Toby A.
    Keeping, Sam
    Park, Julie E.
    Wu, James J.
    Nunes, Ana
    Reitan, John
    Wade, Sally W.
    Salles, Gilles
    LEUKEMIA & LYMPHOMA, 2024, 65 (01) : 14 - 25
  • [49] Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China
    Ying, Zhitao
    Yang, Haiyan
    Guo, Ye
    Li, Wenyu
    Zou, Dehui
    Zhou, Daobin
    Wang, Zhao
    Zhang, Mingzhi
    Wu, Jianqiu
    Liu, Hui
    Zhang, Pian
    Yang, Su
    Zhou, Zisong
    Zheng, Hongxia
    Song, Yuqin
    Zhu, Jun
    CANCER MEDICINE, 2021, 10 (03): : 999 - 1011
  • [50] COST-EFFECTIVENESS ANALYSIS FOR ACALABRUTINIB IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (R/R MCL) IN CHINA
    Chang, S.
    He, X.
    VALUE IN HEALTH, 2024, 27 (06) : S95 - S95
12345